228 related articles for article (PubMed ID: 33345556)
1. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.
Woodis CB; Ghassemi E; McLendon AN
Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556
[TBL] [Abstract][Full Text] [Related]
2. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
Archer DF; Bernick BA; Mirkin S
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
[No Abstract] [Full Text] [Related]
3. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
4. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
5. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
[TBL] [Abstract][Full Text] [Related]
6. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
[TBL] [Abstract][Full Text] [Related]
7. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
[TBL] [Abstract][Full Text] [Related]
8. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
[TBL] [Abstract][Full Text] [Related]
9. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
10. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
[TBL] [Abstract][Full Text] [Related]
11. Estradiol/progesterone (Bijuva) for menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2019 Jul; 61(1575):99-101. PubMed ID: 31381541
[No Abstract] [Full Text] [Related]
12. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
[TBL] [Abstract][Full Text] [Related]
13. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective?
Whelan AM; Jurgens TM; Trinacty M
Ann Pharmacother; 2013 Jan; 47(1):112-6. PubMed ID: 23249728
[TBL] [Abstract][Full Text] [Related]
14. Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.
Liu JH; Black DR; Larkin L; Graham S; Bernick B; Mirkin S
Menopause; 2020 Dec; 27(12):1388-1395. PubMed ID: 32842052
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
[No Abstract] [Full Text] [Related]
16. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study.
Ruiz AD; Daniels KR
Int J Pharm Compd; 2014; 18(1):70-7. PubMed ID: 24881343
[TBL] [Abstract][Full Text] [Related]
17. Initial 17beta-estradiol dose for treating vasomotor symptoms.
Notelovitz M; Lenihan JP; McDermott M; Kerber IJ; Nanavati N; Arce J
Obstet Gynecol; 2000 May; 95(5):726-31. PubMed ID: 10775738
[TBL] [Abstract][Full Text] [Related]
18. Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology.
Cortés-Bonilla M; Bernardo-Escudero R; Alonso-Campero R; Francisco-Doce MT; Hernández-Valencia M; Celis-González C; Márquez-Oñate R; Chedraui P; Uribe JA
Gynecol Endocrinol; 2015 Jul; 31(7):552-9. PubMed ID: 26062108
[TBL] [Abstract][Full Text] [Related]
19. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
